Furthermore, R3mab was able to bind not only wtFGFR3 but also the most common FGFR3 mutants and inhibited proliferation as well as FGFR3 signaling in bladder cancer cells, exhibiting wild type and mutated variants of FGFR3. This evidence concerns the gene FGFR3 and urinary bladder cancer.